Levobupivakain Kabi (Levobupivacaine Hydrochloride)

Levobupivacaine works by reversibly binding to voltage‑gated sodium channels on nerve membranes. This binding stabilises the inactive channel state, preventing sodium influx and thereby inhibiting the initiation and propagation of action potentials. The result is a reversible loss of sensory perception in the area where the drug is administered.

The dose of Levobupivakain Kabi is determined by the prescribing clinician based on the specific procedure, patient characteristics, and route of administration. Healthcare professionals calculate the appropriate volume and concentration to achieve the desired block while staying within recommended maximum limits.

Levobupivakain Kabi is classified as pregnancy category unknown. It should be used during pregnancy only if the potential benefit to the mother outweighs any possible risk to the fetus. Limited data are available for breastfeeding, so caution is advised and the decision should be made by the treating physician.

To order Levobupivakain Kabi, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including cold‑chain if required) and necessary import documentation.

Levobupivakain Kabi contains the S‑enantiomer of bupivacaine, offering a similar duration of action with a lower incidence of cardiotoxicity and central nervous system toxicity compared with racemic bupivacaine. This safety profile makes it a preferred option for prolonged blocks, while maintaining comparable analgesic efficacy.

Levobupivakain Kabi should be stored at controlled room temperature, below 25 °C, in its original packaging. The container should be kept away from direct sunlight, moisture and sources of heat. Inspect the solution for particulate matter or discoloration before use and discard if any abnormalities are observed.

Levobupivakain Kabi is administered by a qualified healthcare professional via epidural, infiltration, intrathecal or peripheral nerve block techniques. The appropriate route, volume and concentration are selected based on the clinical indication and patient factors, and the injection is performed under aseptic conditions.

Serious risks associated with Levobupivakain Kabi include seizures, cardiac arrest, severe hypotension or bradycardia, respiratory depression, allergic reactions such as anaphylaxis, and prolonged motor block. Prompt recognition and supportive management are essential if any of these events occur.

Levobupivakain Kabi should be avoided in patients with known hypersensitivity to levobupivacaine or other amide‑type local anesthetics, in individuals with severe cardiac conduction disorders, and in patients receiving other agents that significantly increase the risk of cardiotoxicity. Caution is also advised for patients with uncontrolled epilepsy or severe hepatic impairment.